What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?

Syndax Pharmaceuticals Inc SNDX shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory (R/R) acute leukemias. 

AML trial of revumenib in combination with venetoclax-decitabine/cedazuridine in R/R AML was featured during an oral session at the 65th American Society of Hematology (ASH) Annual Meeting. 

As of a data cutoff date of November 1, 2023, nine patients were enrolled and response evaluable at the time of the data cut. 

All nine patients attained a morphologic remission for an overall response rate of 100%, 78% of whom achieved a CRc1, including 44% who achieved a CR/CRh. 

67% (6/9) of patients in the trial attained minimal residual disease (MRD) negative status. Five patients transitioned to hematopoietic stem-cell transplantation (HSCT) following response. Two patients initiated post-transplant maintenance with revumenib and continued in remission for over 11 months.

Syndax Pharmaceuticals announced data from the BEAT AML trial of revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML patients. 

Eleven (85%) of 13 patients attained a CR/CRh, and 92% (12/13) attained MRD negative status. Two patients proceeded to transplant.

The company announced data from the AUGMENT-102 trial of revumenib in combination with fludarabine/cytarabine in a predominantly pediatric relapsed/refractory mNPM1 (n=1), NUP98r (n=1) and KMT2Ar (n=13) AML population. 

Among the 12 patients treated at 163 mg q12h, four (33%) patients achieved a CRc, including three (25%) patients who achieved a CR; four (33%) proceeded to transplant.

Price Action: SNDX shares are up 8.9% at $18.14 on the last check Monday.